CMS Selects Trulicity and Biktarvy Among 15 Drugs for Third Medicare Price Negotiation Cycle

CMS announced 15 high-cost drugs, including Eli Lilly's Trulicity (Type 2 diabetes) and Gilead's Biktarvy (HIV), for the third cycle of Medicare Drug Price Negotiation Program, marking the first inclusion of Part B drugs.234

Negotiations occur in 2026, with prices effective January 1, 2028; these drugs accounted for $27 billion in Medicare Part B and D spending.47

One drug, Tradjenta, selected for renegotiation.34

CMS Administrator Dr. Mehmet Oz highlighted the Trump administration's efforts to lower costs for seniors.346

Full list includes Anoro Ellipta, Botox, Cimzia, Cosentyx, Entyvio, Erleada, Kisqali, Lenvima, Orencia, Rexulti, Verzenio, Xeljanz, Xolair.3

Sources:

2. https://www.beckershospitalreview.com/pharmacy/cms-names-15-medications-for-2028-price-negotiation-cycle/

3. https://abcnews.go.com/US/wireStory/trump-administration-announces-15-new-drugs-medicare-price-129617075

4. https://www.cms.gov/newsroom/press-releases/cms-announces-selection-drugs-third-cycle-medicare-drug-price-negotiation-program-including-first

6. https://www.statnews.com/2026/01/27/medicare-drug-price-negotiations-third-round-targets-15-drugs/

7. https://www.pharmaceutical-technology.com/news/cms-selects-next-batch-of-15-high-cost-medicines-for-third-negotiation-cycle/